Publication: Current updates and future perspectives in uric acid research, 2024
dc.contributor.coauthor | Kuwabara, Masanari | |
dc.contributor.coauthor | Ae, Ryusuke | |
dc.contributor.coauthor | Kosami, Koki | |
dc.contributor.coauthor | Andres-Hernando, Ana | |
dc.contributor.coauthor | Hisatome, Ichiro | |
dc.contributor.coauthor | Lanaspa, Miguel A. | |
dc.contributor.department | School of Medicine | |
dc.contributor.kuauthor | Kanbay, Mehmet | |
dc.contributor.schoolcollegeinstitute | SCHOOL OF MEDICINE | |
dc.date.accessioned | 2025-03-06T20:58:30Z | |
dc.date.issued | 2024 | |
dc.description.abstract | Uric acid, the final product of purine metabolism, plays a significant role in hypertension Research on uric acid has advanced significantly, particularly regarding its links to hypertension and cardiovascular disease (CVD). Our 2023 review covered the relationship between uric acid, hypertension;and CVD, however, numerous new studies have emerged since then. This paper provides an update, summarizing recent findings over the past two years on hyperuricemia and its association with hypertension, preeclampsia, arteriosclerosis, kidney disease, sleep-disordered breathing, CVD, and so on. Hyperuricemia, often driven by reduced uric acid excretion or increased production, is influenced by genetic factors and lifestyle habits, including high-purine foods, alcohol, and fructose intake. While hyperuricemia has been proposed to contribute to hypertension and CVD through mechanisms like inflammasome activation and oxidative stress, its causal role remains debated. Further clinical and basic science studies on hyperuricemia and purine metabolism are necessary to clarify its impact on CVD and guide therapeutic approaches. | |
dc.description.indexedby | WOS | |
dc.description.indexedby | Scopus | |
dc.description.indexedby | PubMed | |
dc.description.publisherscope | International | |
dc.description.sponsoredbyTubitakEu | N/A | |
dc.description.sponsorship | This study was supported by research grants from JSPS KAKENHI Grant (20K17168 and 23K07493);the Japanese Society of Gout and Uric and Nucleic Acid;and the Gout and Uric Acid Foundation of Japan | |
dc.identifier.doi | 10.1038/s41440-024-02031-9 | |
dc.identifier.eissn | 1348-4214 | |
dc.identifier.grantno | JSPS KAKENHI Grant [20K17168, 23K07493];Japanese Society of Gout and Uric Nucleic Acid;Gout and Uric Acid Foundation of Japan | |
dc.identifier.issn | 0916-9636 | |
dc.identifier.issue | 2 | |
dc.identifier.quartile | Q1 | |
dc.identifier.scopus | 2-s2.0-85211489419 | |
dc.identifier.uri | https://doi.org/10.1038/s41440-024-02031-9 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14288/27475 | |
dc.identifier.volume | 48 | |
dc.identifier.wos | 1368856500001 | |
dc.keywords | Uric acid | |
dc.keywords | Hyperuricemia | |
dc.keywords | Preeclampsia | |
dc.keywords | Cardiovascular disease | |
dc.keywords | Association | |
dc.language.iso | eng | |
dc.publisher | Springer Nature | |
dc.relation.ispartof | HYPERTENSION RESEARCH | |
dc.subject | Peripheral vascular disease | |
dc.title | Current updates and future perspectives in uric acid research, 2024 | |
dc.type | Review | |
dspace.entity.type | Publication | |
local.contributor.kuauthor | Kanbay, Mehmet | |
local.publication.orgunit1 | SCHOOL OF MEDICINE | |
local.publication.orgunit2 | School of Medicine | |
relation.isOrgUnitOfPublication | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isOrgUnitOfPublication.latestForDiscovery | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isParentOrgUnitOfPublication | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e | |
relation.isParentOrgUnitOfPublication.latestForDiscovery | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e |